Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral
efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining
lamivudine 100mg QD treatment in CHB patients currently receiving lamivudine monotherapy.